Rebalix
LGIM · sheet of 10 September 2026
LGIM · sheet of 10 September 2026ETF sheet · official issuer and register data
L&G Emerging Markets Quality Dividends Equal Weight UCITS ETF
LDME · IE00BMYDMC42 · class USD Dist. · USD · domicile Ireland
Equity · Emerging markets · Real estate · All sizes · Dividend · QualitySFDR art. 8
Index tracked: FTSE Emerging All Cap ex CW ex TC ex REITS Dividend Growth with Quality Index
- TER
- 0.45%+ trans. 0.12%
- Fund size
- 53 m EUR
- Tracking difference
- −1.12%3-year avg
- 🇮🇹 tax rate
- —white list not published
- Replication
- Physical (sampled)
- Income
- Distributingquarterly
Launch 15 Jul 2021 · costs from the KID as of 2 Sept 2026 · 0 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The investment objective of the Fund is to provide exposure to companies across emerging markets that are weighted according to their quality characteristics and pay higher than average dividends. The Fund is passively managed and aims to track the performance of the FTSE Emerging All Cap ex-CW ex-TC ex-REITS Dividend Growth with Quality Net Tax Index (the “Index”), before the deduction of fees and expenses. The Index is designed to provide exposure to companies across emerging markets with higher than average dividend and quality characteristics, in…
Performance since series start (in euro) — base 100
12 Jul 2021 → 31 Jul 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +22.7% |
| 3 years | +51.1% |
| 5 years | +69.1% |
| 10 years | series too young |
| Since series start | +65.4% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 12.48% | 12.18% | 12.34% |
| Max drawdown | −8.33% | −15.60% | −29.13% |
| Sharpe | 1.29 | 0.96 | 0.35 |
| Sortino | 1.90 | 1.35 | 0.48 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · LDME · IE00BMYDMC421
RebalixLDME · IE00BMYDMC42 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +25.39% | +26.22% | −0.83% |
| 2024 | +9.46% | +10.36% | −0.89% |
| 2023 | +17.98% | +19.63% | −1.65% |
| 2022 | −12.36% | −11.81% | −0.55% |
Distributions · per share, in USD
Frequency: quarterly · last 12 months: 0.439 USD (3.18% of NAV) · last ex-date 11 Jun 2026
| Year | Payments | Total (USD) | Dividend yield |
|---|---|---|---|
| 2026 | 2 | 0.1863 | — |
| 2025 | 4 | 0.4268 | +4.33% |
| 2024 | 4 | 0.3825 | +4.08% |
| 2023 | 4 | 0.3458 | +4.19% |
| 2022 | 4 | 0.4162 | +4.21% |
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.
Holdings
Portfolio as declared by the issuer · 30 Jun 2026 · 0 securities · top-10 weight = 4.1%
| Top holdings | Weight |
|---|---|
| 0.5% | |
| 0.4% | |
| 0.4% | |
| 0.4% | |
| 0.4% | |
| 0.4% | |
| 0.4% | |
| 0.4% | |
| 0.4% | |
| 0.4% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
LGGM · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 7 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00BMYDMC42
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BMYDMC42
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · LDME · IE00BMYDMC422